U.S. Physical Therapy (NYSE:USPH) announced its quarterly earnings results on Thursday. The company reported $0.64 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.58 by $0.06, MarketWatch Earnings reports. The company had revenue of $113.10 million for the quarter, compared to analysts’ expectations of $112.79 million. U.S. Physical Therapy had a net margin of 5.03% and a return on equity of 13.81%. The company’s revenue was up 9.8% on a year-over-year basis. U.S. Physical Therapy updated its FY18 guidance to $2.50-2.57 EPS.
USPH traded up $8.04 during midday trading on Thursday, hitting $115.56. 207,800 shares of the company traded hands, compared to its average volume of 59,344. The company has a debt-to-equity ratio of 0.27, a quick ratio of 2.06 and a current ratio of 2.06. The stock has a market capitalization of $1.37 billion, a P/E ratio of 55.87, a P/E/G ratio of 3.83 and a beta of 1.12. U.S. Physical Therapy has a 52 week low of $64.45 and a 52 week high of $129.65.
In other U.S. Physical Therapy news, Director Mark J. Brookner sold 625 shares of the company’s stock in a transaction dated Friday, September 7th. The shares were sold at an average price of $128.50, for a total transaction of $80,312.50. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, COO Glenn Mcdowell sold 6,204 shares of the company’s stock in a transaction dated Friday, August 3rd. The shares were sold at an average price of $114.81, for a total transaction of $712,281.24. The disclosure for this sale can be found here. Insiders have sold a total of 32,054 shares of company stock worth $3,713,012 in the last 90 days. Company insiders own 2.50% of the company’s stock.
USPH has been the topic of several research analyst reports. Zacks Investment Research upgraded shares of U.S. Physical Therapy from a “hold” rating to a “buy” rating and set a $129.00 target price on the stock in a research note on Tuesday, August 7th. Jefferies Financial Group restated a “hold” rating and set a $105.00 target price on shares of U.S. Physical Therapy in a research note on Friday, August 3rd. Finally, Barrington Research restated a “hold” rating on shares of U.S. Physical Therapy in a research note on Friday, August 3rd. Four research analysts have rated the stock with a hold rating, one has issued a buy rating and one has given a strong buy rating to the company’s stock. U.S. Physical Therapy presently has a consensus rating of “Buy” and a consensus price target of $108.00.
About U.S. Physical Therapy
U.S. Physical Therapy, Inc, through its subsidiaries, operates outpatient physical therapy clinics that provide pre-and post-operative care and treatment for orthopedic-related disorders, sports-related injuries, preventative care, rehabilitation of injured workers, and neurological-related injuries.
Read More: Understanding Market Liquidity
Receive News & Ratings for U.S. Physical Therapy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for U.S. Physical Therapy and related companies with MarketBeat.com's FREE daily email newsletter.